Aclaris Therapeutics shows a favorable technical setup with strong momentum, a wide analyst-target upside, and double-digit revenue growth, but quality sits below the exit threshold and insiders have been notable net sellers, keeping the position capped at avoid.
Thesis pillars
- High Asymmetry Strong Momentum→Stable
- Quality Below Floor Exit Signal→Stable
- Notable Insider Selling→Stable
- +2 more pillars — see the Why tab for full reasoning
Aclaris Therapeutics, Inc. (ACRS) Stock Analysis
Inst Constrain edge
Healthcare · Biotechnology
Sell if holding. Engine safety override at $5.64: Quality below floor (2.4 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 6.4/10 and A.R:R 3.9:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality.
Aclaris Therapeutics is a clinical-stage biopharmaceutical company developing small-molecule and biologic product candidates for immuno-inflammatory diseases, using its proprietary KINect kinase-discovery platform alongside licensed antibody programs. Its lead assets include... Read more
Sell if holding. Engine safety override at $5.64: Quality below floor (2.4 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 6.4/10 and A.R:R 3.9:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Score 6.4/10, moderate confidence.
Passes 7/8 gates (positive momentum, favorable risk/reward ratio, no SEC red flags, news events none recent, earnings proximity 29d clear, semi cycle peak clear, materials cycle peak clear). Suitability: speculative.
About Aclaris Therapeutics, Inc.
About Aclaris Therapeutics, Inc.
Aclaris Therapeutics is advancing four clinical-stage immuno-inflammatory product candidates: bosakitug, a monoclonal antibody targeting TSLP with Phase 2 topline data expected in the second half of 2026; ATI-052, a TSLP/IL-4Ra bispecific antibody now in Phase 1b trials for atopic dermatitis and asthma; and the oral ITK/JAK3 inhibitor ATI-2138, which met its primary endpoint in a Phase 2a atopic dermatitis trial in July 2025. The company held $151.4 million in cash and marketable securities as of December 31, 2025, against a $64.9 million net loss for the year.
Aclaris does not intend to commercialize its product candidates alone; its stated strategy is to identify and consummate transactions with third-party partners to further develop, obtain marketing approval for, and commercialize each asset, meaning future revenue depends on striking and executing partnership agreements rather than direct product sales. Both of its lead biologics, bosakitug and ATI-052, are exclusively licensed worldwide (excluding Greater China) from Biosion, Inc., while bosakitug's Greater China rights and development are licensed separately to CTTQ, and the company has licensed its topical JAK inhibitor lepzacitinib's Greater China rights to Pediatrix Therapeutics while still seeking a global partner outside that territory. Aclaris owns no manufacturing facilities and relies entirely on third parties to produce preclinical and clinical drug supply for all of its product candidates.
Show full overview
Aclaris's business model creates a structural dependency most biotechs don't share: because the company explicitly plans to out-license rather than commercialize its own candidates, its eventual revenue hinges not just on clinical trial success but on its ability to negotiate and close partnership agreements on acceptable terms, a step the 10-K flags as a distinct risk on top of ordinary development risk. That dependency is concentrated in a single external licensor, Biosion, which holds the underlying rights to both TSLP-targeting programs, bosakitug and ATI-052, that make up the bulk of the company's near-term clinical catalysts, with topline data across both programs expected through 2026.
See also: Healthcare · Biotechnology
From Aclaris Therapeutics, Inc.'s most recent 10-K filing, extracted July 6, 2026.
Recent developments
updated 2026-07-08Recent Developments — Aclaris Therapeutics, Inc.
Latest news
- NEWS 12 Health Care Stocks Moving In Tuesday's After-Market Session — benzinga Jun 30, 2026 neutral
Generated 2026-07-08T23:03:58Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHcounterpartyBiosion10-K Item 1: 'We exclusively license global rights (excluding Mainland China, Macau, Hong Kong and Taiwan ("Greater China")) to bosakitug from Biosion, Inc.'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker·2 ceiling hits
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $5.64: Quality below floor (2.4 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 6.4/10 and A.R:R 3.9:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $5.12. Score 6.4/10, moderate confidence.
Take-profit target: $8.70 (+57.9% upside). Prior stop was $5.12. Stop-loss: $5.12.
Concentration risk — Counterparty: Biosion; Quality below floor (2.4 < 4.0).
Aclaris Therapeutics, Inc. trades at a P/E of N/A (forward -6.6). TrendMatrix value score: 9.0/10. Verdict: Sell.
18 analysts cover ACRS with a consensus score of 4.3/5. Average price target: $10.
What does Aclaris Therapeutics, Inc. do?Aclaris Therapeutics is a clinical-stage biopharmaceutical company developing small-molecule and biologic product...
Aclaris Therapeutics is a clinical-stage biopharmaceutical company developing small-molecule and biologic product candidates for immuno-inflammatory diseases, using its proprietary KINect kinase-discovery platform alongside licensed antibody programs. Its lead assets include bosakitug and ATI-052, TSLP-targeting antibodies exclusively licensed from Biosion, and internally discovered ITK/JAK inhibitors ATI-2138 and ATI-9494, none of which are FDA-approved; the company reported a $64.9 million net loss in 2025 and $151.4 million in cash and marketable securities.